Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Borrello

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2019
Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor ActivityLuca Biavati, Kimberly Noonan, Leo Luznik, et al.
Cancer Research|July 3, 2008
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cellsPaolo Serafini, Stephanie Mgebroff, Kimberly Noonan, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Hematologic Malignancies: Plasma Cell DisordersMadhav V Dhodapkar, Ivan Borrello, Adam D Cohen, et al.
Journal of the Peripheral Nervous System : JPNS|February 5, 2009
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathyVinay Chaudhry, David R Cornblath, Michael Polydefkis, et al.
British Journal of Haematology|January 19, 2011
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myelomaNilanjan Ghosh, Xiaobu Ye, Anna Ferguson, et al.
Cancer Immunology Research|June 1, 2014
Targeting immune suppression with PDE5 inhibition in end-stage multiple myelomaKimberly A Noonan, Nilanjan Ghosh, Lakshmi Rudraraju, et al.
Journal of Medical Economics|January 4, 2013
Total cost comparison in relapsed/refractory multiple myelomaBrian Durie, Gary Binder, Chris Pashos, et al.
British Journal of Haematology|July 13, 2010
Development of target-specific treatments in multiple myelomaAsher A Chanan-Khan, Ivan Borrello, Kelvin P Lee, et al.
American Journal of Hematology|April 12, 2014
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myelomaNilanjan Ghosh, Noah Tucker, Marianna Zahurak, et al.
Cancer Research|September 3, 2004
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cellsPaolo Serafini, Rebecca Carbley, Kimberly A Noonan, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2019
Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor ActivityLuca Biavati, Kimberly Noonan, Leo Luznik, et al.
Cancer Research|July 3, 2008
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cellsPaolo Serafini, Stephanie Mgebroff, Kimberly Noonan, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Hematologic Malignancies: Plasma Cell DisordersMadhav V Dhodapkar, Ivan Borrello, Adam D Cohen, et al.
Journal of the Peripheral Nervous System : JPNS|February 5, 2009
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathyVinay Chaudhry, David R Cornblath, Michael Polydefkis, et al.
British Journal of Haematology|January 19, 2011
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myelomaNilanjan Ghosh, Xiaobu Ye, Anna Ferguson, et al.
Cancer Immunology Research|June 1, 2014
Targeting immune suppression with PDE5 inhibition in end-stage multiple myelomaKimberly A Noonan, Nilanjan Ghosh, Lakshmi Rudraraju, et al.
Journal of Medical Economics|January 4, 2013
Total cost comparison in relapsed/refractory multiple myelomaBrian Durie, Gary Binder, Chris Pashos, et al.
British Journal of Haematology|July 13, 2010
Development of target-specific treatments in multiple myelomaAsher A Chanan-Khan, Ivan Borrello, Kelvin P Lee, et al.
American Journal of Hematology|April 12, 2014
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myelomaNilanjan Ghosh, Noah Tucker, Marianna Zahurak, et al.
Cancer Research|September 3, 2004
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cellsPaolo Serafini, Rebecca Carbley, Kimberly A Noonan, et al.
Pageof 9